BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/27/2023 5:08:21 PM | Browse: 208 | Download: 625
 |
Received |
|
2023-09-02 14:48 |
|
Peer-Review Started |
|
2023-09-02 14:50 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-10-16 17:49 |
|
Revised |
|
2023-10-29 13:50 |
|
Second Decision |
|
2023-11-10 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-11-14 08:41 |
|
Articles in Press |
|
2023-11-14 08:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-11-22 03:48 |
|
Publish the Manuscript Online |
|
2023-11-27 17:08 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Study |
| Article Title |
Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wen-Ting Peng, Chuan Jiang, Fei-Lan Yang, Nian-Qi Zhou, Ke-Yu Chen, Jin-Qing Liu, Shi-Fang Peng and Lei Fu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82170640, and No. 81974080 |
| Natural Science Foundation of Hunan Province |
No. 2022JJ30954 |
|
| Corresponding Author |
Lei Fu, MD, Professor, Department of Infectious Diseases, Xiangya Hospital Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. fulei92@126.com |
| Key Words |
Alanine transaminase normalization; Chronic hepatitis B; Renal safety; Virological response; Blood lipid; Tenofovir |
| Core Tip |
This is a retrospective study to compare the efficacy and safety of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) for 48 wk in patients with chronic hepatitis B (CHB). Our study found that TMF is as effective as TAF in treating CHB and has comparable safety profiles. In addition, TAF may cause deterioration of lipid profiles. These results suggest that TMF may be a viable alternative to TAF for CHB treatment. |
| Publish Date |
2023-11-27 17:08 |
| Citation |
Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, Peng SF, Fu L. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol 2023; 29(44): 5907-5918 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i44/5907.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i44.5907 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
